

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Sunil Chada *et al.*

Serial No.: 10/791,692

Filed: March 2, 2004

For: METHODS AND COMPOSITIONS  
INVOLVING MDA-7

Group Art Unit: 1743

Examiner: Nagpaul, Jyoti


Atty. Dkt. No.: INGN:105US

Confirmation No.: 3897

**CERTIFICATE OF ELECTRONIC TRANSMISSION**

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

June 8, 2007  
Date



Gina N. Shishima

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INGN:105US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima  
Reg. No. 45,104  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: June 8, 2007

Form PTO-1449 (modified)		Atty. Docket No.: INGN:105US	Serial No.: 10/791,692
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: March 2, 2004	Group: 1743
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C290	Chada <i>et al.</i> , "mda-7/IL24 Kills Pancreatic Cancer Cells by Inhibition of the Wnt/PI3K Signaling Pathways: Identification of IL-20 Receptor-Mediated Bystander Activity against Pancreatic Cancer," <i>Mol. Ther.</i> , 11(5):724-733, 2005.
	C291	Inoue <i>et al.</i> , "Inhibition of Src Kinase Activity by Ad-md7 Suppresses Vascular Endothelial Growth Factor Expression in Prostate Carcinoma Cells," <i>Mol. Ther.</i> , 12:707-715, 2005.
	C292	Mellinghoff <i>et al.</i> , "Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors," <i>New Eng. J. Med.</i> , 353:2012-2024, 2006.
	C293	Normano <i>et al.</i> , "The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib," <i>J. Cell Physiol.</i> , 207:420-427, 2006.
	C294	Sutter <i>et al.</i> , "Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer," <i>Int. J. Cancer</i> , 118:1814-1822, 2006.
	C295	Xia <i>et al.</i> , "A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer," <i>Proc. Natl. Acad. Sci. USA</i> , 103:7795-7800, 2006.

25785026.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.